Foraviset Named Lead Research Partner for the Women's Health Infrastructure Report

Boston, MA — 19 August 2026 — Women's HealthX has officially confirmed Foravisét as the exclusive Lead Research Partner for the upcoming 2026 U.S. Women's Health Infrastructure Report.

As the healthcare sector faces escalating pressure from tightening federal compliance mandates and shifting commercial frameworks, this landmark intelligence dossier will provide the definitive cross-functional benchmark for the industry going into the 2027 fiscal year.

Who is Foravisét?

Foravisét is a women's-health biopharmaceutical company developing Raviset®, a first-in-class investigational non-hormonal therapy for endometriosis.

Foravisét's therapeutic approach is centered on modulation of the iNOS/NO pathway, an upstream biological axis implicated in inflammation, pain signaling, tissue injury and broader uterine physiology. Raviset is advancing toward controlled Phase IIa clinical validation in endometriosis, supported by prior human exposure, a robust nonclinical and pharmacokinetic foundation, and historical gynecologic clinical experience. Foravisét is building its development strategy around a persistent challenge in women's health: translating emerging biological insight and clinical evidence into differentiated treatment options for conditions where substantial unmet need persists and therapeutic innovation significantly lags behind disease burden.

What Will They Contribute?

As exclusive Lead Research Partner, Foravisét will bring a women's-health research, clinical-development and therapeutic-innovation perspective to the development of the report. Working alongside Women's HealthX, the company will contribute to the research framework and interpretation of findings, bringing its perspective to the evidence, capabilities and structural factors shaping women's health across the U.S. healthcare landscape.

Foravisét's perspective is informed by the practical challenges of developing new therapies in women's health—from understanding disease biology and generating meaningful clinical evidence to navigating treatment pathways and the conditions that ultimately determine whether innovation can reach patients.

A Unified Boardroom Dossier

The completed 30-page intelligence report, dropping in September, will completely bypass abstract industry rhetoric. With Foravisét contributing its women's-health research and clinical-development perspective, the report will map how health plans, hospital systems and enterprise employers are approaching upcoming budgets, service-line priorities and investment decisions across women's health. Healthcare operators and industry strategists can contribute 60 seconds of their operational insight to verify their parameters and secure an early, pre-ordered copy of the dossier below.